Evidence map›Paper›PMID 37045827›Full record

ReviewSignal transduction and targeted therapy2023

Patient-derived xenograft models in cancer therapy: technologies and applications.

Yihan Liu, Wantao Wu, Changjing Cai, Hao Zhang, Hong Shen, Ying Han

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07554677 (Feasibility of a Co-designed PRe-radiotherapy Exercise Programme for People With Stage I-III Non-small Cell Lung cAnCEr), which is not on this map. Cited by 319 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
319citing papers in PubMed, 5 pooled it
90.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07554677 narecruitingnot on this mapstarted 2026, after this paper: background citation

Feasibility of a Co-designed PRe-radiotherapy Exercise Programme for People With Stage I-III Non-small Cell Lung cAnCEr: A Single-centre, Single Arm Pilot Study

TypeinterventionalSponsorQueen's University, BelfastRan2026 to 2026Enrolled30ConditionsLung CancerArmsExercise, radiotherapy
3 · Its place in the literature

Who cites it

319 citing papers in PubMed, 5 syntheses or guidelines pooled it, 394 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Genome stability disrupted by the circRBM39(4,5,6)-RPA2 axis represses breast tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

259 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yihan Liu *Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Wantao Wu *Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Changjing CaiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Hao ZhangDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hong ShenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. hongshen2000@csu.edu.cn.
Ying HanDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. yinghan@csu.edu.cn.
Central South University · CNXiangya Hospital Central South University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted into immunocompromised or humanized mice, have shown superiority in recapitulating the characteristics of cancer, such as the spatial structure of cancer and the intratumor heterogeneity of cancer. Moreover, PDX models retain the genomic features of patients across different stages, subtypes, and diversified treatment backgrounds. Optimized PDX engraftment procedures and modern technologies such as multi-omics and deep learning have enabled a more comprehensive depiction of the PDX molecular landscape and boosted the utilization of PDX models. These irreplaceable advantages make PDX models an ideal choice in cancer treatment studies, such as preclinical trials of novel drugs, validating novel drug combinations, screening drug-sensitive patients, and exploring drug resistance mechanisms. In this review, we gave an overview of the history of PDX models and the process of PDX model establishment. Subsequently, the review presents the strengths and weaknesses of PDX models and highlights the integration of novel technologies in PDX model research. Finally, we delineated the broad application of PDX models in chemotherapy, targeted therapy, immunotherapy, and other novel therapies.

Indexed as

NeoplasmsAnimalsHeterograftsHumansImmunotherapyMice

Identifiers

PMID37045827
PMCPMC10097874
OpenAlexW4365148379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.